{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:39:46Z","timestamp":1793230786330,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40120-024-00584-y","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T06:02:36Z","timestamp":1707717756000},"page":"449-464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Understanding the Symptoms and Impacts Experienced by People with Relapsing\u2013Remitting MS: A Qualitative Investigation Using Semi-Structured Interviews"],"prefix":"10.1007","volume":"13","author":[{"given":"Amy","family":"Barrett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oyebimpe","family":"Olayinka-Amao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trishna","family":"Bharadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Henke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kamudoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"issue":"1","key":"584_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43.","journal-title":"Nat Rev Dis Primers"},{"issue":"9648","key":"584_CR2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502\u201317.","journal-title":"Lancet"},{"issue":"12","key":"584_CR3","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133(12):1380-90.e2.","journal-title":"Am J Med"},{"issue":"6","key":"584_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/JNN.0b013e318268308b","volume":"44","author":"PK Newland","year":"2012","unstructured":"Newland PK, Thomas FP, Riley M, Flick LH, Fearing A. The use of focus groups to characterize symptoms in persons with multiple sclerosis. J Neurosci Nurs. 2012;44(6):351\u20137.","journal-title":"J Neurosci Nurs"},{"issue":"3","key":"584_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.7224\/1537-2073.2012-053","volume":"15","author":"I Kister","year":"2013","unstructured":"Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, Herbert J. Natural history of multiple sclerosis symptoms. Int J MS Care. 2013;15(3):146\u201358.","journal-title":"Int J MS Care"},{"key":"584_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.msard.2018.07.013","volume":"25","author":"L Barin","year":"2018","unstructured":"Barin L, Salmen A, Disanto G, et al. The disease burden of multiple sclerosis from the individual and population perspective: which symptoms matter most? Mult Scler Relat Disord. 2018;25:112\u201321.","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"584_CR7","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1177\/1352458518799580","volume":"25","author":"PS Rommer","year":"2019","unstructured":"Rommer PS, Eichst\u00e4dt K, Ellenberger D, et al. Symptomatology and symptomatic treatment in multiple sclerosis: results from a nationwide MS registry. Mult Scler J. 2019;25(12):1641\u201352.","journal-title":"Mult Scler J"},{"issue":"2_suppl","key":"584_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/1352458516650741","volume":"22","author":"P Feys","year":"2016","unstructured":"Feys P, Giovannoni G, Dijsselbloem N, Centonze D, Eelen P, Lykke AS. The importance of a multi-disciplinary perspective and patient activation programmes in MS management. Mult Scler J. 2016;22(2_suppl):34\u201346.","journal-title":"Mult Scler J"},{"issue":"1","key":"584_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann T, Moccia M, Coetzee T, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023;22(1):78\u201388.","journal-title":"Lancet Neurol"},{"key":"584_CR10","doi-asserted-by":"publisher","unstructured":"Giovannoni G, Popescu V, Wuerfel J, et al. Smouldering multiple sclerosis: the 'real MS'. Ther Adv Neurol Disord. 2022;15. https:\/\/doi.org\/10.1177\/17562864211066751.","DOI":"10.1177\/17562864211066751"},{"issue":"7","key":"584_CR11","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jamaneurol.2022.1025","volume":"79","author":"A Cagol","year":"2022","unstructured":"Cagol A, Schaedelin S, Barakovic M, et al. Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis. JAMA Neurol. 2022;79(7):682\u201392.","journal-title":"JAMA Neurol"},{"issue":"14","key":"584_CR12","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1177\/1352458518814117","volume":"25","author":"C Elliott","year":"2019","unstructured":"Elliott C, Wolinsky JS, Hauser SL, et al. Slowly expanding\/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Mult Scler. 2019;25(14):1915\u201325.","journal-title":"Mult Scler"},{"issue":"5","key":"584_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Hollenbach JA, Bove R, et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019;85(5):653\u201366.","journal-title":"Ann Neurol"},{"issue":"11","key":"584_CR14","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1093\/brain\/awaa275","volume":"143","author":"M Sucksdorff","year":"2020","unstructured":"Sucksdorff M, Matilainen M, Tuisku J, et al. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis. Brain. 2020;143(11):3318\u201330.","journal-title":"Brain"},{"issue":"9","key":"584_CR15","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132\u201340.","journal-title":"JAMA Neurol"},{"key":"584_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.628542","volume":"11","author":"H Inojosa","year":"2020","unstructured":"Inojosa H, Proschmann U, Akg\u00fcn K, Ziemssen T. Should we use clinical tools to identify disease progression? Front Neurol. 2020;11:628542.","journal-title":"Front Neurol"},{"issue":"10","key":"584_CR17","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1177\/1352458520936231","volume":"27","author":"C Thrue","year":"2021","unstructured":"Thrue C, Riemenschneider M, Hvid L, Stenager E, Dalgas U. Time matters: early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains. Mult Scler J. 2021;27(10):1477\u201385.","journal-title":"Mult Scler J"},{"key":"584_CR18","doi-asserted-by":"crossref","first-page":"205520762311735","DOI":"10.1177\/20552076231173520","volume":"9","author":"S Mountford","year":"2023","unstructured":"Mountford S, Kahn M, Balakrishnan P, et al. Correlation and differences of patient-reported outcomes vs. Likert-rating of MS symptoms in a real-world cohort using a digital patient app. Digit Health. 2023;9:20552076231173520.","journal-title":"Digit Health"},{"issue":"1","key":"584_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2340\/16501977-0002","volume":"39","author":"F Khan","year":"2007","unstructured":"Khan F, Pallant JF. Use of International Classification of Functioning, Disability and Health (ICF) to describe patient-reported disability in multiple sclerosis and identification of relevant environmental factors. J Rehabil Med. 2007;39(1):63\u201370.","journal-title":"J Rehabil Med"},{"issue":"5","key":"584_CR20","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1177\/1054773815592817","volume":"25","author":"PK Newland","year":"2016","unstructured":"Newland PK, Lorenz R, Budhathoki C, Jensen MP. The presence of symptoms with comorbid conditions in individuals with multiple sclerosis (MS). Clin Nurs Res. 2016;25(5):532\u201348.","journal-title":"Clin Nurs Res"},{"issue":"8","key":"584_CR21","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1177\/1352458520958369","volume":"27","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Taylor BV, Simpson S, et al. Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with multiple sclerosis, irrespective of clinical phenotype. Mult Scler J. 2021;27(8):1262\u201375.","journal-title":"Mult Scler J"},{"issue":"11","key":"584_CR22","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol. 1983;33(11):1444\u201352.","journal-title":"Neurol"},{"issue":"2","key":"584_CR23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373.","journal-title":"Lancet Neurol"},{"issue":"5","key":"584_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102512","volume":"19","author":"H Inojosa","year":"2020","unstructured":"Inojosa H, Schriefer D, Ziemssen T. Clinical outcome measures in multiple sclerosis: a review. Autoimmun Rev. 2020;19(5):102512.","journal-title":"Autoimmun Rev"},{"key":"584_CR25","doi-asserted-by":"publisher","first-page":"103165","DOI":"10.1016\/j.msard.2021.103165","volume":"55","author":"CAA van\u2019t Hullenaar","year":"2021","unstructured":"van\u2019t Hullenaar CAA, Coerver E, Kalkers NF, et al. The use of multi-domain patient reported outcome measures for detecting clinical disease progression in multiple sclerosis. Mult Scler Relat Disord. 2021;55:103165.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"584_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jval.2018.11.007","volume":"22","author":"S Hudgens","year":"2019","unstructured":"Hudgens S, Schuler R, Stokes J, Eremenco S, Hunsche E, Leist TP. Development and validation of the FSIQ-RMS: a new patient-reported questionnaire to assess symptoms and impacts of fatigue in relapsing multiple sclerosis. Value Health. 2019;22(4):453\u201366.","journal-title":"Value Health"},{"key":"584_CR27","doi-asserted-by":"crossref","unstructured":"Kamudoni P, Johns J, Cook KF, et al. Standardizing fatigue measurement in multiple sclerosis: the validity, responsiveness and score interpretation of the PROMIS SF v1.0 Fatigue (MS) 8a. Mult Scler Relat Disord. 2021;54:103117.","DOI":"10.1016\/j.msard.2021.103117"},{"key":"584_CR28","doi-asserted-by":"crossref","unstructured":"Prakash RS, Schirda B, Valentine TR, Crotty M, Nicholas JA. Emotion dysregulation in multiple sclerosis: Impact on symptoms of depression and anxiety. Mult Scler Relat Disord. 2019;36:101399.","DOI":"10.1016\/j.msard.2019.101399"},{"key":"584_CR29","unstructured":"Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims. 2009. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm193282.pdf. Accessed 14 Apr 2023."},{"key":"584_CR30","unstructured":"European Medical Agency. Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/03\/WC500185161.pdf. Accessed 14 Apr 2023."},{"key":"584_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103757","volume":"61","author":"P Zaratin","year":"2022","unstructured":"Zaratin P, Vermersch P, Amato MP, Brichetto G, Coetzee T, Cutter G, et al. The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. Mult Scler Relat Disord. 2022;61: 103757.","journal-title":"Mult Scler Relat Disord"},{"key":"584_CR32","doi-asserted-by":"crossref","unstructured":"Scholz M, Haase R, Trentzsch K, St\u00f6lzer-Hutsch H, Ziemssen T. Improving Digital Patient Care: Lessons Learned from Patient-Reported and Expert-Reported Experience Measures for the Clinical Practice of Multidimensional Walking Assessment. Brain Sci. 2021;11(6):786.","DOI":"10.3390\/brainsci11060786"},{"key":"584_CR33","doi-asserted-by":"crossref","unstructured":"Kamudoni P, Amtmann D, Johns J, et al. The validity, responsiveness, and score interpretation of the PROMISnq Physical Function Multiple Sclerosis 15a short form in multiple sclerosis. Mult Scler Relat Disord. 2022;62:103753.","DOI":"10.1016\/j.msard.2022.103753"},{"issue":"3","key":"584_CR34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1053\/sonu.2001.25948","volume":"17","author":"MZ Cohen","year":"2001","unstructured":"Cohen MZ, Phillips JM, Palos G. Qualitative research with diverse populations. Semin Oncol Nurs. 2001;17(3):190\u20136.","journal-title":"Semin Oncol Nurs"},{"key":"584_CR35","doi-asserted-by":"crossref","unstructured":"Mateen FJ. Is It Time for Quotas to Achieve Racial and Ethnic Representation in Multiple Sclerosis Trials? Front Neurol. 2021;12:680912.","DOI":"10.3389\/fneur.2021.680912"},{"key":"584_CR36","doi-asserted-by":"crossref","unstructured":"Westergaard K, Skovgaard L, Magyari M, Kristiansen M. Patient perspectives on patient-reported outcomes in multiple sclerosis treatment trajectories: A qualitative study of why, what, and how? Mult Scler Relat Disord. 2022;58:103475.","DOI":"10.1016\/j.msard.2021.103475"},{"key":"584_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.msard.2019.06.024","volume":"35","author":"LS Matza","year":"2019","unstructured":"Matza LS, Stewart KD, Phillips G, Delio P, Naismith RT. Development of a brief clinician-reported outcome measure of multiple sclerosis signs and symptoms: the Clinician Rating of Multiple Sclerosis (CRoMS). Mult Scler Relat Disord. 2019;35:253\u201361.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"584_CR38","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2165\/11591150-000000000-00000","volume":"4","author":"NG Larocca","year":"2011","unstructured":"Larocca NG. Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient. 2011;4(3):189\u2013201.","journal-title":"Patient"},{"key":"584_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103355","volume":"57","author":"FJ Campos-Lucas","year":"2022","unstructured":"Campos-Lucas FJ, Fern\u00e1ndez-Fern\u00e1ndez \u00d3, Monge-Mart\u00edn D, Moral-Torres E, Carrascal-Rueda P, Caballero-Mart\u00ednez F. The evolution of multiple sclerosis in Spain over the last decade from the patient\u2019s perspective. Mult Scler Relat Disord. 2022;57: 103355.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"584_CR40","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/1352458514544538","volume":"21","author":"AM Harrison","year":"2015","unstructured":"Harrison AM, Bogosian A, Silber E, McCracken LM, Moss-Morris R. \u201cIt feels like someone is hammering my feet\u201d: understanding pain and its management from the perspective of people with multiple sclerosis. Mult Scler. 2015;21(4):466\u201376.","journal-title":"Mult Scler"},{"key":"584_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102046","volume":"41","author":"J Maurino","year":"2020","unstructured":"Maurino J, Mart\u00ednez-Gin\u00e9s ML, Garc\u00eda-Dom\u00ednguez JM, et al. Workplace difficulties, health-related quality of life, and perception of stigma from the perspective of patients with multiple sclerosis. Mult Scler Relat Disord. 2020;41:102046.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"584_CR42","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1471-6712.2008.00633.x","volume":"23","author":"M Krokavcova","year":"2009","unstructured":"Krokavcova M, Van Dijk JP, Nagyova I, et al. Perceived health status as measured by the SF-36 in patients with multiple sclerosis: a review. Scand J Caring Sci. 2009;23(3):529\u201338.","journal-title":"Scand J Caring Sci"},{"key":"584_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.msard.2019.05.019","volume":"33","author":"E D'Amico","year":"2019","unstructured":"D\u2019Amico E, Haase R, Ziemssen T. Review: Patient-reported outcomes in multiple sclerosis care. Mult Scler Relat Disord. 2019;33:61\u20136.","journal-title":"Mult Scler Relat Disord"},{"key":"584_CR44","unstructured":"European Medical Agency. Qualification opinion on multiple sclerosis clinical outcome assessment (MSCOA). 2020. https:\/\/www.ema.europa.eu\/en\/documents\/other\/qualification-opinion-multiple-sclerosis-clinical-outcome-assessment-mscoa_en.pdf. Accessed 14 Apr 2023."},{"key":"584_CR45","unstructured":"Food and Drug Administration. Clinical Outcome Assessments (COA) qualification program submissions. 2021. https:\/\/www.fda.gov\/drugs\/clinical-outcome-assessment-coa-qualification-program\/clinical-outcome-assessments-coa-qualification-program-submissions. Accessed 14 Apr 2023."},{"issue":"5","key":"584_CR46","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1177\/1352458517690821","volume":"23","author":"RH Benedict","year":"2017","unstructured":"Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler J. 2017;23(5):721\u201333.","journal-title":"Mult Scler J"},{"issue":"2","key":"584_CR47","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.gaitpost.2011.09.005","volume":"35","author":"RW Motl","year":"2012","unstructured":"Motl RW, Weikert M, Suh Y, et al. Accuracy of the actibelt\u00ae accelerometer for measuring walking speed in a controlled environment among persons with multiple sclerosis. Gait Posture. 2012;35(2):192\u20136.","journal-title":"Gait Posture"},{"issue":"Suppl 1","key":"584_CR48","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/S0022-510X(11)70009-0","volume":"311","author":"T Ziemssen","year":"2011","unstructured":"Ziemssen T. Symptom management in patients with multiple sclerosis. J Neurol Sci. 2011;311(Suppl 1):S48\u201352.","journal-title":"J Neurol Sci"},{"issue":"8","key":"584_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103358","volume":"22","author":"I Voigt","year":"2023","unstructured":"Voigt I, Inojosa H, Wenk J, Akg\u00fcn K, Ziemssen T. Building a monitoring matrix for the management of multiple sclerosis. Autoimmun Rev. 2023;22(8):103358.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"584_CR50","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/1352458516638941","volume":"23","author":"D Cadavid","year":"2017","unstructured":"Cadavid D, Cohen JA, Freedman MS, et al. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler J. 2017;23(1):94\u2013105.","journal-title":"Mult Scler J"},{"key":"584_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101861","volume":"38","author":"T Ziemssen","year":"2020","unstructured":"Ziemssen T, Tolley C, Bennett B, et al. A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: physicians\u2019 and patients\u2019 views. Mult Scler Relat Disord. 2020;38:101861.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"584_CR52","first-page":"205521732211056","volume":"8","author":"T Bharadia","year":"2022","unstructured":"Bharadia T, Vandercappellen J, Chitnis T, et al. Patient-reported outcome measures in MS: do development processes and patient involvement support valid quantification of clinically important variables? Mult Scler J Exp Transl Clin. 2022;8(2):20552173221105640.","journal-title":"Mult Scler J Exp Transl Clin"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00584-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00584-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00584-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T15:26:14Z","timestamp":1710861974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00584-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["584"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00584-y","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"15 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amy Barrett and Oyebimpe Olayinka-Amao are employees of RTI Health Solutions. Tjalf Ziemssen reports consulting or serving on speaker bureaus for Biogen, Celgene, Roche, Novartis, Celgene, Merck Healthcare KGaA, Darmstadt, Germany, and Sanofi, as well as research support from Biogen, Novartis, Merck Healthcare KGaA, Darmstadt, Germany, and Sanofi. Trishna Bharadia has received honoraria and\/or consulting fees from AbbVie, Becaris, King\u2019s College London, Lumanity, Blue Latitude Health, Curatio, University College London, MS International Federation, Future Science Group, Savvy Cooperative, WEGO Health, Prime Global, Eyeforpharma, Professional Record Standards Body, DODS D&I, Queen Mary University London, Merck Healthcare KGaA, Darmstadt, Germany, The Method, Clara Health, The Conference Forum, Greenphire, Hollister, Medable, Oxford Health Policy Forum, College of Contemporary Health, Pfizer, Bristol Myers Squibb, UCB, Medidata, Talking Medicines, Pivot Digital, NHS England, Boeringher Ingelheim, MSD, Novartis, Parexel, Roche, Roche Information Solutions, Teva, and Sandoz. Christian Henke and Paul Kamudoni are employees of Merck Healthcare KGaA, Darmstadt, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Ethical approvals were obtained from RTI\u2019s Institutional Review Board (ID number 14206). The research was performed in accordance with the protocol, the provisions of the International Conference on Harmonisation, the Declaration of Helsinki, and applicable local regulatory requirements and laws.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}